Guardant Health (GH) just unveiled an update.
Guardant Health, Inc. expanded its Board of Directors to nine members with the appointment of Dr. Manuel Hidalgo Medina, a distinguished expert in oncology and anticancer drug development, particularly in gastrointestinal cancers. Dr. Hidalgo, who currently leads Hematology and Medical Oncology at Weill Cornell Medicine, will serve on the Guardant Health Board until the 2026 Annual Meeting of Stockholders. In addition to his academic and clinical achievements, Dr. Hidalgo holds a board position at Bristol-Myers Squibb and brings valuable leadership experience from prestigious institutions such as Harvard Medical School and the Spanish National Cancer Research Centre.
See more data about GH stock on TipRanks’ Stock Analysis page.
